Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 (a) Genetic backbone of pECPB39 (MG886287) and pKP13a (CP003996) plasmids. In pECPB39, the ΔproP-mcr-5.3-chrB ... Figure 1 (a) Genetic backbone.

Published byΚλωπᾶς Λειβαδάς Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 (a) Genetic backbone of pECPB39 (MG886287) and pKP13a (CP003996) plasmids. In pECPB39, the ΔproP-mcr-5.3-chrB ... Figure 1 (a) Genetic backbone."— Presentation transcript:

1 Figure 1 (a) Genetic backbone of pECPB39 (MG886287) and pKP13a (CP003996) plasmids. In pECPB39, the ΔproP-mcr-5.3-chrB ... Figure 1 (a) Genetic backbone of pECPB39 (MG886287) and pKP13a (CP003996) plasmids. In pECPB39, the ΔproP-mcr-5.3-chrB array has been incorporated into the pKP13a backbone. In fact, the mcr-5.3 gene is embedded within a Tn3-family transposon with a 38 bp IRL, as previously reported.<sup>3</sup> DUF, domain of unknown function proteins. (b) Comparison of MCR-5-type phosphoethanolamine transferase proteins of S. enterica subsp. enterica serovar Paratyphi B and E. coli strains identified in Germany<sup>3</sup><sup>,</sup><sup>4</sup> and Brazil (this study). The position of the amino acid deletion in MCR-5.2 (Glu233) is indicated by a dash (highlighted in grey), whereas the amino acid substitution in MCR-5.3 (Ala414Ser) is indicated in bold (highlighted in grey). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 73, Issue 12, 07 September 2018, Pages 3520–3522, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 (a) Genetic backbone of pECPB39 (MG886287) and pKP13a (CP003996) plasmids. In pECPB39, the ΔproP-mcr-5.3-chrB ... Figure 1 (a) Genetic backbone."

Similar presentations

Figure 1. Direct evidence for the acquisition and demise of Tn6330 by DNA sequence alignment. (a) Comparison between ... Figure 1. Direct evidence for.

Figure 1. Direct evidence for the acquisition and demise of Tn6330 by DNA sequence alignment. (a) Comparison between ... Figure 1. Direct evidence for.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1. Colistin MIC distribution for the 153 colistin-resistant E

Figure 1. Colistin MIC distribution for the 153 colistin-resistant E
Figure 1. Structure of resistance islands containing dfrA35 in IncC plasmids. (a) pEc158 resistance island and (b) ... Figure 1. Structure of resistance.

Figure 1. Structure of resistance islands containing dfrA35 in IncC plasmids. (a) pEc158 resistance island and (b) ... Figure 1. Structure of resistance.
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.
Figure 1. Structure of two poxtA-carrying plasmids in E

Figure 1. Structure of two poxtA-carrying plasmids in E
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.
Figure 1. SpeI-PFGE dendrogram comparing P

Figure 1. SpeI-PFGE dendrogram comparing P
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Similar presentations

Ads by Google